
How Regulators are Setting Standards for Digital Health Technologies
Expert Insights from ADDS Atlanta 2026

Regulatory standards are quickly adapting to keep pace with digital health technologies and clinical research innovation. In this featured session from the ADDS 2026 conference, leading regulatory authorities from the U.S. Food and Drug Administration (FDA), alongside industry leaders, share data-backed insights on developing digital health technology (DHT) and pre-competitive consortia intelligence towards clinical research adoption.
Across four featured presentations, selected oral abstracts, and an regulatory panel discussion, these exclusive on-demand presentations highlight new opportunities and collaborative pathways to build regulatory-ready solutions.
Register to watch the Featured Presentations and Panel Discussion and hear how industry leaders are applying official guidance, generating rigorous evidence, and using pre-competitive strategies for real-world clinical trial assessments.
Regulatory Session Featured Presentations

Advancing Regulatory Science for Clinical Outcome Assessments: Applying Guidance to Develop Novel Digital Endpoints
Michelle Campbell, PhD
U.S. Food and Drug Administration (FDA)

Regulatory Engagements as a Pre-Competitive Consortium: DECODE Perspective

Sylvain Zorman, PhD
Ametris

Why DECODE-Obesity: Qualitative Evidence Supports Sensor-based Outcomes for Physical Function

Jay Trudeau, PhD
Eli Lilly & Company

Finding Needles in a Haystack: Where we are with a Regulatory-Endorsed Digital Endpoint for ALS
Collin Hovinga
Critical Path Institute (C-Path)
AI Session Panel Discussion

Watch the full session to hear how industry leaders are turning AI-driven insights into scalable, regulatory-ready solutions for modern clinical research and development.
